A new study by cardiologists at The University of Kansas Hospital shows that the heavily advertised cholesterol drug ezetimibe (brand name Zetia; in combination with simvastatin: Vytorin) doesn’t provide all of the benefits suggested in the ads. The study appears in The Journal of Clinical Medical Research.

Ezetimibe is known to lower LDL cholesterol in many patients, but does not have well-defined benefits such as reducing the risk of heart attack, stroke or total mortality. Higher LDL levels are associated with greater risk for a heart attack. But the study involving 3,827 patients showed while ezetimibe did lower LDL cholesterol by 12 percent, it had no measurable effect on total mortality.